OneMedNet (ONMD) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 declined 56% year-over-year to $0.1 million, driven by the planned discontinuation of the BEAM platform and lower web imaging deliveries.

• Net loss for Q3 2024 was $2.1 million, compared to $13.8 million in Q3 2023, reflecting lower stock warrant expenses and changes in fair value of financial instruments.

• The company continues to focus on transitioning from BEAM to iRWD sales, with BEAM customer renewals largely halted.

Financial highlights

• Q3 2024 total revenue: $0.1 million, down 56% year-over-year.

• Gross margin was negative, with cost of revenue exceeding revenue due to lower sales and higher consulting costs.

• Operating expenses increased 18% year-over-year to $2.3 million, mainly from higher general and administrative costs.

• Net loss for the nine months ended September 30, 2024 was $7.8 million, a 75% improvement from $31.3 million in the prior year period.

• Cash and cash equivalents as of September 30, 2024 were $1.9 million, with an additional $2.2 million in Bitcoin holdings.

Outlook and guidance

• Management does not believe current cash and equivalents are sufficient to meet foreseeable cash needs for the next 12 months.

• Plans to raise additional capital through debt and equity offerings to fund operations and support growth.

• The company is transitioning away from BEAM to focus on iRWD, expecting further revenue declines from BEAM in 2025.